Global Postpartum Bleeding Drug Market
Global Postpartum Bleeding Drug Market

Postpartum Bleeding Drug Comprehensive Study by Type (Oxytocin, Methergine, Hemabate, Misoprostol, Carboprost, Tranexamic acid, Others), End-user (Hospitals, Maternity Clinics, Out-of-hospital emergency care), Drug Delivery (Oral, Parenetal, Inhaled form, Intravenous/Intramuscular) Players and Region - Global Market Outlook to 2026

Postpartum Bleeding Drug Market Segmented into XX Submarkets. | Forecast Years: 2021- 2026  

Feb 2021 Edition 210 Pages 216 Tables & Figures
  • Summary
  • Market Segments
  • Table of Content
  • List of Tables & Figures
  • Companies Mentioned
Postpartum Bleeding Drug Market Scope
Postpartum hemorrhage (PPH) or postpartum bleeding is a condition representing significant blood loss after the child birth in adult females or new mothers. Postpartum hemorrhage (PPH) for vaginal birth is 500ml wherein for cesarean, around 1,000ml of blood loss. In severe case, the hemorrhage may lead to hemorrhage or shock from blood loss, as an outcome of rise in the normal plasma volume. Postpartum Bleeding Drug are the prescribed medications to treat the blood loss. Some uterotonic agents’ such as oxytocin, prostaglandins, ergot alkaloids, and others are used to stimulate the contraction of the myometrium, which limits the spiral arteries resulting into reduction in the blood flow through uterus.

The Postpartum Bleeding Drug market study is segmented by Type (Oxytocin, Methergine, Hemabate, Misoprostol, Carboprost, Tranexamic acid and Others) and major geographies with country level break-up.

Research Analyst at AMA estimates that Players concentration is mainly in United States Players will contribute to the maximum growth of Global Postpartum Bleeding Drug market throughout the predicted period.

Lupin Pharmaceuticals (India), GlaxoSmithKline plc. (United Kingdom), Pfizer Inc. (United States), BD (United States), Teva Pharmaceutical Industries Ltd. (Israel), Fresenius Kabi AG (Germany), Baxter Healthcare Corporation (United States), Novartis AG (Switzerland), Par Pharmaceuticals (United States) and Utah Medical Products (United States) are some of the key players that are part of study coverage.

About Approach
The research aims to propose a patent-based approach in searching for potential technology partners as a supporting tool for enabling open innovation. The study also proposes a systematic searching process of technology partners as a
preliminary step to select the emerging and key players that are involved in implementing market estimations. While patent analysis is employed to overcome the aforementioned data- and process-related limitations, as expenses occurred in that technology allows us to estimate the market size by evolving segments as target market from total available market.

Segmentation Overview
AdvanceMarketAnalytics has segmented the market of Global Postpartum Bleeding Drug market by Type, Application and Region.

On the basis of geography, the market of Postpartum Bleeding Drug has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico).

Market Leaders and their expansionary development strategies
In May 2018, Granules Pharmaceuticals, Inc., a part of Granules India Ltd., entered into partnership with the West-Ward Pharmaceuticals Corp., a subsidiary of Hikma Pharmaceuticals PLC to introduce the generic version of Methylergonovine Maleate Tablets, USP, 0.2mg, the generic equivalent to Methergine.
In July 2019, Dr. Reddy’s Laboratories introduced Carboprost Tromethamine Injection USP, 250mcg/mL (1mL), a generic version of Hemabate (Pfizer) as a Competitive Generic Therapy (CGT) for postpartum bleeding.


Market Trend
  • Ongoing research for development of new drug formulations

Market Drivers
  • Growing prevalence of postpartum related deaths
  • Favourable government strategies to prevent postpartum hemorrhage


Restraints
  • Side effects associated with different postpartum bleeding drug

Challenges
  • Availability of alternative treatments to treat postpartum hemorrhage


Key Target Audience
Manufacturer of Delivery Hemorrhage Drugs

Frequently asked questions:
1. Is it possible to have certain customization in the study?
The Study can be customized to meet your requirements. Please connect with our representative, who will ensure you get a study that suits your business objectives.

2. How big is the Postpartum Bleeding Drug Market?
Yes, the study does represent market size by key business segment, application/end users and major geographies forecasted till 2026.

Report Objectives / Segmentation Covered
By Type
  • Oxytocin
  • Methergine
  • Hemabate
  • Misoprostol
  • Carboprost
  • Tranexamic acid
  • Others
By End-user
  • Hospitals
  • Maternity Clinics
  • Out-of-hospital emergency care

By Drug Delivery
  • Oral
  • Parenetal
  • Inhaled form
  • Intravenous/Intramuscular

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Growing prevalence of postpartum related deaths
      • 3.2.2. Favourable government strategies to prevent postpartum hemorrhage
    • 3.3. Market Challenges
      • 3.3.1. Availability of alternative treatments to treat postpartum hemorrhage
    • 3.4. Market Trends
      • 3.4.1. Ongoing research for development of new drug formulations
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Postpartum Bleeding Drug, by Type, End-user, Drug Delivery and Region (value) (2015-2020)
    • 5.1. Introduction
    • 5.2. Global Postpartum Bleeding Drug (Value)
      • 5.2.1. Global Postpartum Bleeding Drug by: Type (Value)
        • 5.2.1.1. Oxytocin
        • 5.2.1.2. Methergine
        • 5.2.1.3. Hemabate
        • 5.2.1.4. Misoprostol
        • 5.2.1.5. Carboprost
        • 5.2.1.6. Tranexamic acid
        • 5.2.1.7. Others
      • 5.2.2. Global Postpartum Bleeding Drug by: End-user (Value)
        • 5.2.2.1. Hospitals
        • 5.2.2.2. Maternity Clinics
        • 5.2.2.3. Out-of-hospital emergency care
      • 5.2.3. Global Postpartum Bleeding Drug by: Drug Delivery (Value)
        • 5.2.3.1. Oral
        • 5.2.3.2. Parenetal
        • 5.2.3.3. Inhaled form
        • 5.2.3.4. Intravenous/Intramuscular
      • 5.2.4. Global Postpartum Bleeding Drug Region
        • 5.2.4.1. South America
          • 5.2.4.1.1. Brazil
          • 5.2.4.1.2. Argentina
          • 5.2.4.1.3. Rest of South America
        • 5.2.4.2. Asia Pacific
          • 5.2.4.2.1. China
          • 5.2.4.2.2. Japan
          • 5.2.4.2.3. India
          • 5.2.4.2.4. South Korea
          • 5.2.4.2.5. Taiwan
          • 5.2.4.2.6. Australia
          • 5.2.4.2.7. Rest of Asia-Pacific
        • 5.2.4.3. Europe
          • 5.2.4.3.1. Germany
          • 5.2.4.3.2. France
          • 5.2.4.3.3. Italy
          • 5.2.4.3.4. United Kingdom
          • 5.2.4.3.5. Netherlands
          • 5.2.4.3.6. Rest of Europe
        • 5.2.4.4. MEA
          • 5.2.4.4.1. Middle East
          • 5.2.4.4.2. Africa
        • 5.2.4.5. North America
          • 5.2.4.5.1. United States
          • 5.2.4.5.2. Canada
          • 5.2.4.5.3. Mexico
  • 6. Postpartum Bleeding Drug: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2020)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. Lupin Pharmaceuticals (India)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. GlaxoSmithKline plc. (United Kingdom)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Pfizer Inc. (United States)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. BD (United States)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Teva Pharmaceutical Industries Ltd. (Israel)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Fresenius Kabi AG (Germany)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Baxter Healthcare Corporation (United States)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. Novartis AG (Switzerland)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. Par Pharmaceuticals (United States)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
      • 6.4.10. Utah Medical Products (United States)
        • 6.4.10.1. Business Overview
        • 6.4.10.2. Products/Services Offerings
        • 6.4.10.3. Financial Analysis
        • 6.4.10.4. SWOT Analysis
  • 7. Global Postpartum Bleeding Drug Sale, by Type, End-user, Drug Delivery and Region (value) (2021-2026)
    • 7.1. Introduction
    • 7.2. Global Postpartum Bleeding Drug (Value)
      • 7.2.1. Global Postpartum Bleeding Drug by: Type (Value)
        • 7.2.1.1. Oxytocin
        • 7.2.1.2. Methergine
        • 7.2.1.3. Hemabate
        • 7.2.1.4. Misoprostol
        • 7.2.1.5. Carboprost
        • 7.2.1.6. Tranexamic acid
        • 7.2.1.7. Others
      • 7.2.2. Global Postpartum Bleeding Drug by: End-user (Value)
        • 7.2.2.1. Hospitals
        • 7.2.2.2. Maternity Clinics
        • 7.2.2.3. Out-of-hospital emergency care
      • 7.2.3. Global Postpartum Bleeding Drug by: Drug Delivery (Value)
        • 7.2.3.1. Oral
        • 7.2.3.2. Parenetal
        • 7.2.3.3. Inhaled form
        • 7.2.3.4. Intravenous/Intramuscular
      • 7.2.4. Global Postpartum Bleeding Drug Region
        • 7.2.4.1. South America
          • 7.2.4.1.1. Brazil
          • 7.2.4.1.2. Argentina
          • 7.2.4.1.3. Rest of South America
        • 7.2.4.2. Asia Pacific
          • 7.2.4.2.1. China
          • 7.2.4.2.2. Japan
          • 7.2.4.2.3. India
          • 7.2.4.2.4. South Korea
          • 7.2.4.2.5. Taiwan
          • 7.2.4.2.6. Australia
          • 7.2.4.2.7. Rest of Asia-Pacific
        • 7.2.4.3. Europe
          • 7.2.4.3.1. Germany
          • 7.2.4.3.2. France
          • 7.2.4.3.3. Italy
          • 7.2.4.3.4. United Kingdom
          • 7.2.4.3.5. Netherlands
          • 7.2.4.3.6. Rest of Europe
        • 7.2.4.4. MEA
          • 7.2.4.4.1. Middle East
          • 7.2.4.4.2. Africa
        • 7.2.4.5. North America
          • 7.2.4.5.1. United States
          • 7.2.4.5.2. Canada
          • 7.2.4.5.3. Mexico
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Postpartum Bleeding Drug: by Type(USD Million)
  • Table 2. Postpartum Bleeding Drug Oxytocin , by Region USD Million (2015-2020)
  • Table 3. Postpartum Bleeding Drug Methergine , by Region USD Million (2015-2020)
  • Table 4. Postpartum Bleeding Drug Hemabate , by Region USD Million (2015-2020)
  • Table 5. Postpartum Bleeding Drug Misoprostol , by Region USD Million (2015-2020)
  • Table 6. Postpartum Bleeding Drug Carboprost , by Region USD Million (2015-2020)
  • Table 7. Postpartum Bleeding Drug Tranexamic acid , by Region USD Million (2015-2020)
  • Table 8. Postpartum Bleeding Drug Others , by Region USD Million (2015-2020)
  • Table 9. Postpartum Bleeding Drug: by End-user(USD Million)
  • Table 10. Postpartum Bleeding Drug Hospitals , by Region USD Million (2015-2020)
  • Table 11. Postpartum Bleeding Drug Maternity Clinics , by Region USD Million (2015-2020)
  • Table 12. Postpartum Bleeding Drug Out-of-hospital emergency care , by Region USD Million (2015-2020)
  • Table 13. Postpartum Bleeding Drug: by Drug Delivery(USD Million)
  • Table 14. Postpartum Bleeding Drug Oral , by Region USD Million (2015-2020)
  • Table 15. Postpartum Bleeding Drug Parenetal , by Region USD Million (2015-2020)
  • Table 16. Postpartum Bleeding Drug Inhaled form , by Region USD Million (2015-2020)
  • Table 17. Postpartum Bleeding Drug Intravenous/Intramuscular , by Region USD Million (2015-2020)
  • Table 18. South America Postpartum Bleeding Drug, by Country USD Million (2015-2020)
  • Table 19. South America Postpartum Bleeding Drug, by Type USD Million (2015-2020)
  • Table 20. South America Postpartum Bleeding Drug, by End-user USD Million (2015-2020)
  • Table 21. South America Postpartum Bleeding Drug, by Drug Delivery USD Million (2015-2020)
  • Table 22. Brazil Postpartum Bleeding Drug, by Type USD Million (2015-2020)
  • Table 23. Brazil Postpartum Bleeding Drug, by End-user USD Million (2015-2020)
  • Table 24. Brazil Postpartum Bleeding Drug, by Drug Delivery USD Million (2015-2020)
  • Table 25. Argentina Postpartum Bleeding Drug, by Type USD Million (2015-2020)
  • Table 26. Argentina Postpartum Bleeding Drug, by End-user USD Million (2015-2020)
  • Table 27. Argentina Postpartum Bleeding Drug, by Drug Delivery USD Million (2015-2020)
  • Table 28. Rest of South America Postpartum Bleeding Drug, by Type USD Million (2015-2020)
  • Table 29. Rest of South America Postpartum Bleeding Drug, by End-user USD Million (2015-2020)
  • Table 30. Rest of South America Postpartum Bleeding Drug, by Drug Delivery USD Million (2015-2020)
  • Table 31. Asia Pacific Postpartum Bleeding Drug, by Country USD Million (2015-2020)
  • Table 32. Asia Pacific Postpartum Bleeding Drug, by Type USD Million (2015-2020)
  • Table 33. Asia Pacific Postpartum Bleeding Drug, by End-user USD Million (2015-2020)
  • Table 34. Asia Pacific Postpartum Bleeding Drug, by Drug Delivery USD Million (2015-2020)
  • Table 35. China Postpartum Bleeding Drug, by Type USD Million (2015-2020)
  • Table 36. China Postpartum Bleeding Drug, by End-user USD Million (2015-2020)
  • Table 37. China Postpartum Bleeding Drug, by Drug Delivery USD Million (2015-2020)
  • Table 38. Japan Postpartum Bleeding Drug, by Type USD Million (2015-2020)
  • Table 39. Japan Postpartum Bleeding Drug, by End-user USD Million (2015-2020)
  • Table 40. Japan Postpartum Bleeding Drug, by Drug Delivery USD Million (2015-2020)
  • Table 41. India Postpartum Bleeding Drug, by Type USD Million (2015-2020)
  • Table 42. India Postpartum Bleeding Drug, by End-user USD Million (2015-2020)
  • Table 43. India Postpartum Bleeding Drug, by Drug Delivery USD Million (2015-2020)
  • Table 44. South Korea Postpartum Bleeding Drug, by Type USD Million (2015-2020)
  • Table 45. South Korea Postpartum Bleeding Drug, by End-user USD Million (2015-2020)
  • Table 46. South Korea Postpartum Bleeding Drug, by Drug Delivery USD Million (2015-2020)
  • Table 47. Taiwan Postpartum Bleeding Drug, by Type USD Million (2015-2020)
  • Table 48. Taiwan Postpartum Bleeding Drug, by End-user USD Million (2015-2020)
  • Table 49. Taiwan Postpartum Bleeding Drug, by Drug Delivery USD Million (2015-2020)
  • Table 50. Australia Postpartum Bleeding Drug, by Type USD Million (2015-2020)
  • Table 51. Australia Postpartum Bleeding Drug, by End-user USD Million (2015-2020)
  • Table 52. Australia Postpartum Bleeding Drug, by Drug Delivery USD Million (2015-2020)
  • Table 53. Rest of Asia-Pacific Postpartum Bleeding Drug, by Type USD Million (2015-2020)
  • Table 54. Rest of Asia-Pacific Postpartum Bleeding Drug, by End-user USD Million (2015-2020)
  • Table 55. Rest of Asia-Pacific Postpartum Bleeding Drug, by Drug Delivery USD Million (2015-2020)
  • Table 56. Europe Postpartum Bleeding Drug, by Country USD Million (2015-2020)
  • Table 57. Europe Postpartum Bleeding Drug, by Type USD Million (2015-2020)
  • Table 58. Europe Postpartum Bleeding Drug, by End-user USD Million (2015-2020)
  • Table 59. Europe Postpartum Bleeding Drug, by Drug Delivery USD Million (2015-2020)
  • Table 60. Germany Postpartum Bleeding Drug, by Type USD Million (2015-2020)
  • Table 61. Germany Postpartum Bleeding Drug, by End-user USD Million (2015-2020)
  • Table 62. Germany Postpartum Bleeding Drug, by Drug Delivery USD Million (2015-2020)
  • Table 63. France Postpartum Bleeding Drug, by Type USD Million (2015-2020)
  • Table 64. France Postpartum Bleeding Drug, by End-user USD Million (2015-2020)
  • Table 65. France Postpartum Bleeding Drug, by Drug Delivery USD Million (2015-2020)
  • Table 66. Italy Postpartum Bleeding Drug, by Type USD Million (2015-2020)
  • Table 67. Italy Postpartum Bleeding Drug, by End-user USD Million (2015-2020)
  • Table 68. Italy Postpartum Bleeding Drug, by Drug Delivery USD Million (2015-2020)
  • Table 69. United Kingdom Postpartum Bleeding Drug, by Type USD Million (2015-2020)
  • Table 70. United Kingdom Postpartum Bleeding Drug, by End-user USD Million (2015-2020)
  • Table 71. United Kingdom Postpartum Bleeding Drug, by Drug Delivery USD Million (2015-2020)
  • Table 72. Netherlands Postpartum Bleeding Drug, by Type USD Million (2015-2020)
  • Table 73. Netherlands Postpartum Bleeding Drug, by End-user USD Million (2015-2020)
  • Table 74. Netherlands Postpartum Bleeding Drug, by Drug Delivery USD Million (2015-2020)
  • Table 75. Rest of Europe Postpartum Bleeding Drug, by Type USD Million (2015-2020)
  • Table 76. Rest of Europe Postpartum Bleeding Drug, by End-user USD Million (2015-2020)
  • Table 77. Rest of Europe Postpartum Bleeding Drug, by Drug Delivery USD Million (2015-2020)
  • Table 78. MEA Postpartum Bleeding Drug, by Country USD Million (2015-2020)
  • Table 79. MEA Postpartum Bleeding Drug, by Type USD Million (2015-2020)
  • Table 80. MEA Postpartum Bleeding Drug, by End-user USD Million (2015-2020)
  • Table 81. MEA Postpartum Bleeding Drug, by Drug Delivery USD Million (2015-2020)
  • Table 82. Middle East Postpartum Bleeding Drug, by Type USD Million (2015-2020)
  • Table 83. Middle East Postpartum Bleeding Drug, by End-user USD Million (2015-2020)
  • Table 84. Middle East Postpartum Bleeding Drug, by Drug Delivery USD Million (2015-2020)
  • Table 85. Africa Postpartum Bleeding Drug, by Type USD Million (2015-2020)
  • Table 86. Africa Postpartum Bleeding Drug, by End-user USD Million (2015-2020)
  • Table 87. Africa Postpartum Bleeding Drug, by Drug Delivery USD Million (2015-2020)
  • Table 88. North America Postpartum Bleeding Drug, by Country USD Million (2015-2020)
  • Table 89. North America Postpartum Bleeding Drug, by Type USD Million (2015-2020)
  • Table 90. North America Postpartum Bleeding Drug, by End-user USD Million (2015-2020)
  • Table 91. North America Postpartum Bleeding Drug, by Drug Delivery USD Million (2015-2020)
  • Table 92. United States Postpartum Bleeding Drug, by Type USD Million (2015-2020)
  • Table 93. United States Postpartum Bleeding Drug, by End-user USD Million (2015-2020)
  • Table 94. United States Postpartum Bleeding Drug, by Drug Delivery USD Million (2015-2020)
  • Table 95. Canada Postpartum Bleeding Drug, by Type USD Million (2015-2020)
  • Table 96. Canada Postpartum Bleeding Drug, by End-user USD Million (2015-2020)
  • Table 97. Canada Postpartum Bleeding Drug, by Drug Delivery USD Million (2015-2020)
  • Table 98. Mexico Postpartum Bleeding Drug, by Type USD Million (2015-2020)
  • Table 99. Mexico Postpartum Bleeding Drug, by End-user USD Million (2015-2020)
  • Table 100. Mexico Postpartum Bleeding Drug, by Drug Delivery USD Million (2015-2020)
  • Table 101. Company Basic Information, Sales Area and Its Competitors
  • Table 102. Company Basic Information, Sales Area and Its Competitors
  • Table 103. Company Basic Information, Sales Area and Its Competitors
  • Table 104. Company Basic Information, Sales Area and Its Competitors
  • Table 105. Company Basic Information, Sales Area and Its Competitors
  • Table 106. Company Basic Information, Sales Area and Its Competitors
  • Table 107. Company Basic Information, Sales Area and Its Competitors
  • Table 108. Company Basic Information, Sales Area and Its Competitors
  • Table 109. Company Basic Information, Sales Area and Its Competitors
  • Table 110. Company Basic Information, Sales Area and Its Competitors
  • Table 111. Postpartum Bleeding Drug: by Type(USD Million)
  • Table 112. Postpartum Bleeding Drug Oxytocin , by Region USD Million (2021-2026)
  • Table 113. Postpartum Bleeding Drug Methergine , by Region USD Million (2021-2026)
  • Table 114. Postpartum Bleeding Drug Hemabate , by Region USD Million (2021-2026)
  • Table 115. Postpartum Bleeding Drug Misoprostol , by Region USD Million (2021-2026)
  • Table 116. Postpartum Bleeding Drug Carboprost , by Region USD Million (2021-2026)
  • Table 117. Postpartum Bleeding Drug Tranexamic acid , by Region USD Million (2021-2026)
  • Table 118. Postpartum Bleeding Drug Others , by Region USD Million (2021-2026)
  • Table 119. Postpartum Bleeding Drug: by End-user(USD Million)
  • Table 120. Postpartum Bleeding Drug Hospitals , by Region USD Million (2021-2026)
  • Table 121. Postpartum Bleeding Drug Maternity Clinics , by Region USD Million (2021-2026)
  • Table 122. Postpartum Bleeding Drug Out-of-hospital emergency care , by Region USD Million (2021-2026)
  • Table 123. Postpartum Bleeding Drug: by Drug Delivery(USD Million)
  • Table 124. Postpartum Bleeding Drug Oral , by Region USD Million (2021-2026)
  • Table 125. Postpartum Bleeding Drug Parenetal , by Region USD Million (2021-2026)
  • Table 126. Postpartum Bleeding Drug Inhaled form , by Region USD Million (2021-2026)
  • Table 127. Postpartum Bleeding Drug Intravenous/Intramuscular , by Region USD Million (2021-2026)
  • Table 128. South America Postpartum Bleeding Drug, by Country USD Million (2021-2026)
  • Table 129. South America Postpartum Bleeding Drug, by Type USD Million (2021-2026)
  • Table 130. South America Postpartum Bleeding Drug, by End-user USD Million (2021-2026)
  • Table 131. South America Postpartum Bleeding Drug, by Drug Delivery USD Million (2021-2026)
  • Table 132. Brazil Postpartum Bleeding Drug, by Type USD Million (2021-2026)
  • Table 133. Brazil Postpartum Bleeding Drug, by End-user USD Million (2021-2026)
  • Table 134. Brazil Postpartum Bleeding Drug, by Drug Delivery USD Million (2021-2026)
  • Table 135. Argentina Postpartum Bleeding Drug, by Type USD Million (2021-2026)
  • Table 136. Argentina Postpartum Bleeding Drug, by End-user USD Million (2021-2026)
  • Table 137. Argentina Postpartum Bleeding Drug, by Drug Delivery USD Million (2021-2026)
  • Table 138. Rest of South America Postpartum Bleeding Drug, by Type USD Million (2021-2026)
  • Table 139. Rest of South America Postpartum Bleeding Drug, by End-user USD Million (2021-2026)
  • Table 140. Rest of South America Postpartum Bleeding Drug, by Drug Delivery USD Million (2021-2026)
  • Table 141. Asia Pacific Postpartum Bleeding Drug, by Country USD Million (2021-2026)
  • Table 142. Asia Pacific Postpartum Bleeding Drug, by Type USD Million (2021-2026)
  • Table 143. Asia Pacific Postpartum Bleeding Drug, by End-user USD Million (2021-2026)
  • Table 144. Asia Pacific Postpartum Bleeding Drug, by Drug Delivery USD Million (2021-2026)
  • Table 145. China Postpartum Bleeding Drug, by Type USD Million (2021-2026)
  • Table 146. China Postpartum Bleeding Drug, by End-user USD Million (2021-2026)
  • Table 147. China Postpartum Bleeding Drug, by Drug Delivery USD Million (2021-2026)
  • Table 148. Japan Postpartum Bleeding Drug, by Type USD Million (2021-2026)
  • Table 149. Japan Postpartum Bleeding Drug, by End-user USD Million (2021-2026)
  • Table 150. Japan Postpartum Bleeding Drug, by Drug Delivery USD Million (2021-2026)
  • Table 151. India Postpartum Bleeding Drug, by Type USD Million (2021-2026)
  • Table 152. India Postpartum Bleeding Drug, by End-user USD Million (2021-2026)
  • Table 153. India Postpartum Bleeding Drug, by Drug Delivery USD Million (2021-2026)
  • Table 154. South Korea Postpartum Bleeding Drug, by Type USD Million (2021-2026)
  • Table 155. South Korea Postpartum Bleeding Drug, by End-user USD Million (2021-2026)
  • Table 156. South Korea Postpartum Bleeding Drug, by Drug Delivery USD Million (2021-2026)
  • Table 157. Taiwan Postpartum Bleeding Drug, by Type USD Million (2021-2026)
  • Table 158. Taiwan Postpartum Bleeding Drug, by End-user USD Million (2021-2026)
  • Table 159. Taiwan Postpartum Bleeding Drug, by Drug Delivery USD Million (2021-2026)
  • Table 160. Australia Postpartum Bleeding Drug, by Type USD Million (2021-2026)
  • Table 161. Australia Postpartum Bleeding Drug, by End-user USD Million (2021-2026)
  • Table 162. Australia Postpartum Bleeding Drug, by Drug Delivery USD Million (2021-2026)
  • Table 163. Rest of Asia-Pacific Postpartum Bleeding Drug, by Type USD Million (2021-2026)
  • Table 164. Rest of Asia-Pacific Postpartum Bleeding Drug, by End-user USD Million (2021-2026)
  • Table 165. Rest of Asia-Pacific Postpartum Bleeding Drug, by Drug Delivery USD Million (2021-2026)
  • Table 166. Europe Postpartum Bleeding Drug, by Country USD Million (2021-2026)
  • Table 167. Europe Postpartum Bleeding Drug, by Type USD Million (2021-2026)
  • Table 168. Europe Postpartum Bleeding Drug, by End-user USD Million (2021-2026)
  • Table 169. Europe Postpartum Bleeding Drug, by Drug Delivery USD Million (2021-2026)
  • Table 170. Germany Postpartum Bleeding Drug, by Type USD Million (2021-2026)
  • Table 171. Germany Postpartum Bleeding Drug, by End-user USD Million (2021-2026)
  • Table 172. Germany Postpartum Bleeding Drug, by Drug Delivery USD Million (2021-2026)
  • Table 173. France Postpartum Bleeding Drug, by Type USD Million (2021-2026)
  • Table 174. France Postpartum Bleeding Drug, by End-user USD Million (2021-2026)
  • Table 175. France Postpartum Bleeding Drug, by Drug Delivery USD Million (2021-2026)
  • Table 176. Italy Postpartum Bleeding Drug, by Type USD Million (2021-2026)
  • Table 177. Italy Postpartum Bleeding Drug, by End-user USD Million (2021-2026)
  • Table 178. Italy Postpartum Bleeding Drug, by Drug Delivery USD Million (2021-2026)
  • Table 179. United Kingdom Postpartum Bleeding Drug, by Type USD Million (2021-2026)
  • Table 180. United Kingdom Postpartum Bleeding Drug, by End-user USD Million (2021-2026)
  • Table 181. United Kingdom Postpartum Bleeding Drug, by Drug Delivery USD Million (2021-2026)
  • Table 182. Netherlands Postpartum Bleeding Drug, by Type USD Million (2021-2026)
  • Table 183. Netherlands Postpartum Bleeding Drug, by End-user USD Million (2021-2026)
  • Table 184. Netherlands Postpartum Bleeding Drug, by Drug Delivery USD Million (2021-2026)
  • Table 185. Rest of Europe Postpartum Bleeding Drug, by Type USD Million (2021-2026)
  • Table 186. Rest of Europe Postpartum Bleeding Drug, by End-user USD Million (2021-2026)
  • Table 187. Rest of Europe Postpartum Bleeding Drug, by Drug Delivery USD Million (2021-2026)
  • Table 188. MEA Postpartum Bleeding Drug, by Country USD Million (2021-2026)
  • Table 189. MEA Postpartum Bleeding Drug, by Type USD Million (2021-2026)
  • Table 190. MEA Postpartum Bleeding Drug, by End-user USD Million (2021-2026)
  • Table 191. MEA Postpartum Bleeding Drug, by Drug Delivery USD Million (2021-2026)
  • Table 192. Middle East Postpartum Bleeding Drug, by Type USD Million (2021-2026)
  • Table 193. Middle East Postpartum Bleeding Drug, by End-user USD Million (2021-2026)
  • Table 194. Middle East Postpartum Bleeding Drug, by Drug Delivery USD Million (2021-2026)
  • Table 195. Africa Postpartum Bleeding Drug, by Type USD Million (2021-2026)
  • Table 196. Africa Postpartum Bleeding Drug, by End-user USD Million (2021-2026)
  • Table 197. Africa Postpartum Bleeding Drug, by Drug Delivery USD Million (2021-2026)
  • Table 198. North America Postpartum Bleeding Drug, by Country USD Million (2021-2026)
  • Table 199. North America Postpartum Bleeding Drug, by Type USD Million (2021-2026)
  • Table 200. North America Postpartum Bleeding Drug, by End-user USD Million (2021-2026)
  • Table 201. North America Postpartum Bleeding Drug, by Drug Delivery USD Million (2021-2026)
  • Table 202. United States Postpartum Bleeding Drug, by Type USD Million (2021-2026)
  • Table 203. United States Postpartum Bleeding Drug, by End-user USD Million (2021-2026)
  • Table 204. United States Postpartum Bleeding Drug, by Drug Delivery USD Million (2021-2026)
  • Table 205. Canada Postpartum Bleeding Drug, by Type USD Million (2021-2026)
  • Table 206. Canada Postpartum Bleeding Drug, by End-user USD Million (2021-2026)
  • Table 207. Canada Postpartum Bleeding Drug, by Drug Delivery USD Million (2021-2026)
  • Table 208. Mexico Postpartum Bleeding Drug, by Type USD Million (2021-2026)
  • Table 209. Mexico Postpartum Bleeding Drug, by End-user USD Million (2021-2026)
  • Table 210. Mexico Postpartum Bleeding Drug, by Drug Delivery USD Million (2021-2026)
  • Table 211. Research Programs/Design for This Report
  • Table 212. Key Data Information from Secondary Sources
  • Table 213. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Postpartum Bleeding Drug: by Type USD Million (2015-2020)
  • Figure 5. Global Postpartum Bleeding Drug: by End-user USD Million (2015-2020)
  • Figure 6. Global Postpartum Bleeding Drug: by Drug Delivery USD Million (2015-2020)
  • Figure 7. South America Postpartum Bleeding Drug Share (%), by Country
  • Figure 8. Asia Pacific Postpartum Bleeding Drug Share (%), by Country
  • Figure 9. Europe Postpartum Bleeding Drug Share (%), by Country
  • Figure 10. MEA Postpartum Bleeding Drug Share (%), by Country
  • Figure 11. North America Postpartum Bleeding Drug Share (%), by Country
  • Figure 12. Global Postpartum Bleeding Drug share by Players 2020 (%)
  • Figure 13. Global Postpartum Bleeding Drug share by Players (Top 3) 2020(%)
  • Figure 14. Global Postpartum Bleeding Drug share by Players (Top 5) 2020(%)
  • Figure 15. BCG Matrix for key Companies
  • Figure 16. Lupin Pharmaceuticals (India) Revenue, Net Income and Gross profit
  • Figure 17. Lupin Pharmaceuticals (India) Revenue: by Geography 2020
  • Figure 18. GlaxoSmithKline plc. (United Kingdom) Revenue, Net Income and Gross profit
  • Figure 19. GlaxoSmithKline plc. (United Kingdom) Revenue: by Geography 2020
  • Figure 20. Pfizer Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 21. Pfizer Inc. (United States) Revenue: by Geography 2020
  • Figure 22. BD (United States) Revenue, Net Income and Gross profit
  • Figure 23. BD (United States) Revenue: by Geography 2020
  • Figure 24. Teva Pharmaceutical Industries Ltd. (Israel) Revenue, Net Income and Gross profit
  • Figure 25. Teva Pharmaceutical Industries Ltd. (Israel) Revenue: by Geography 2020
  • Figure 26. Fresenius Kabi AG (Germany) Revenue, Net Income and Gross profit
  • Figure 27. Fresenius Kabi AG (Germany) Revenue: by Geography 2020
  • Figure 28. Baxter Healthcare Corporation (United States) Revenue, Net Income and Gross profit
  • Figure 29. Baxter Healthcare Corporation (United States) Revenue: by Geography 2020
  • Figure 30. Novartis AG (Switzerland) Revenue, Net Income and Gross profit
  • Figure 31. Novartis AG (Switzerland) Revenue: by Geography 2020
  • Figure 32. Par Pharmaceuticals (United States) Revenue, Net Income and Gross profit
  • Figure 33. Par Pharmaceuticals (United States) Revenue: by Geography 2020
  • Figure 34. Utah Medical Products (United States) Revenue, Net Income and Gross profit
  • Figure 35. Utah Medical Products (United States) Revenue: by Geography 2020
  • Figure 36. Global Postpartum Bleeding Drug: by Type USD Million (2021-2026)
  • Figure 37. Global Postpartum Bleeding Drug: by End-user USD Million (2021-2026)
  • Figure 38. Global Postpartum Bleeding Drug: by Drug Delivery USD Million (2021-2026)
  • Figure 39. South America Postpartum Bleeding Drug Share (%), by Country
  • Figure 40. Asia Pacific Postpartum Bleeding Drug Share (%), by Country
  • Figure 41. Europe Postpartum Bleeding Drug Share (%), by Country
  • Figure 42. MEA Postpartum Bleeding Drug Share (%), by Country
  • Figure 43. North America Postpartum Bleeding Drug Share (%), by Country
Some of the key companies/manufacturers profiled in the report
  • Lupin Pharmaceuticals (India)
  • GlaxoSmithKline plc. (United Kingdom)
  • Pfizer Inc. (United States)
  • BD (United States)
  • Teva Pharmaceutical Industries Ltd. (Israel)
  • Fresenius Kabi AG (Germany)
  • Baxter Healthcare Corporation (United States)
  • Novartis AG (Switzerland)
  • Par Pharmaceuticals (United States)
  • Utah Medical Products (United States)
Select License Type
Sample Report Enquiry Before Buy Request Discount

Speak with Analyst

Want to find out more about this report?

Get Free Consultation